Chardan Capital Reiterates “Buy” Rating for REGENXBIO (NASDAQ:RGNX)

REGENXBIO (NASDAQ:RGNX)‘s stock had its “buy” rating reissued by stock analysts at Chardan Capital in a research note issued to investors on Thursday,Benzinga reports. They presently have a $52.00 price target on the biotechnology company’s stock. Chardan Capital’s price objective indicates a potential upside of 365.95% from the stock’s previous close.

Other analysts have also issued research reports about the stock. Barclays started coverage on shares of REGENXBIO in a research report on Tuesday. They issued an “overweight” rating and a $37.00 target price on the stock. Royal Bank Of Canada raised their price objective on REGENXBIO from $17.00 to $19.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Leerink Partners upped their target price on REGENXBIO from $16.00 to $20.00 and gave the stock an “outperform” rating in a report on Monday, December 15th. HC Wainwright reissued a “buy” rating and set a $34.00 price target on shares of REGENXBIO in a research note on Tuesday, October 7th. Finally, Wall Street Zen raised REGENXBIO from a “sell” rating to a “hold” rating in a research note on Monday, November 24th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $30.00.

REGENXBIO Stock Down 3.8%

Shares of RGNX stock opened at $11.16 on Thursday. The business has a fifty day simple moving average of $13.72 and a 200 day simple moving average of $11.31. The company has a market cap of $564.92 million, a P/E ratio of -3.22 and a beta of 1.07. REGENXBIO has a twelve month low of $5.03 and a twelve month high of $16.19.

REGENXBIO (NASDAQ:RGNX) last posted its earnings results on Thursday, November 6th. The biotechnology company reported ($1.20) EPS for the quarter, topping analysts’ consensus estimates of ($1.38) by $0.18. REGENXBIO had a negative net margin of 110.29% and a negative return on equity of 78.29%. The firm had revenue of $29.73 million during the quarter, compared to analysts’ expectations of $24.41 million. As a group, equities research analysts anticipate that REGENXBIO will post -4.84 earnings per share for the current fiscal year.

Institutional Trading of REGENXBIO

A number of institutional investors have recently bought and sold shares of the company. AQR Capital Management LLC grew its stake in REGENXBIO by 2,247.7% during the first quarter. AQR Capital Management LLC now owns 620,595 shares of the biotechnology company’s stock worth $4,437,000 after purchasing an additional 594,161 shares during the period. Jane Street Group LLC boosted its holdings in shares of REGENXBIO by 151.1% during the 1st quarter. Jane Street Group LLC now owns 414,067 shares of the biotechnology company’s stock worth $2,961,000 after buying an additional 249,156 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its position in shares of REGENXBIO by 78.4% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 30,630 shares of the biotechnology company’s stock worth $268,000 after buying an additional 13,458 shares during the period. CWM LLC grew its position in shares of REGENXBIO by 75.4% during the 2nd quarter. CWM LLC now owns 46,816 shares of the biotechnology company’s stock worth $384,000 after buying an additional 20,120 shares during the period. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of REGENXBIO in the 2nd quarter valued at $1,453,000. Institutional investors own 88.08% of the company’s stock.

Key REGENXBIO News

Here are the key news stories impacting REGENXBIO this week:

• Positive Sentiment: Chardan Capital reaffirmed a “buy” on RGNX and set a $52 price target, signaling strong upside from current levels. Chardan Reaffirmation
• Neutral Sentiment: Zacks notes RGNX recently jumped on higher volume (a 5.4% move) but warns that recent downward earnings‑estimate revisions could limit near‑term upside; investors should watch subsequent analyst revisions. Zacks: Soars 5.4%
• Positive Sentiment: Leerink (reported by Yahoo Finance) called the earlier selloff “an overreaction” to the clinical hold, suggesting a recovery is possible if forthcoming safety data and disclosures calm investors. Leerink Commentary
• Negative Sentiment: The U.S. FDA placed clinical holds on RGX‑111 and RGX‑121 following identification of a tumor in a trial participant (disclosed in a Form 8‑K on Jan. 28), a direct driver of the recent sharp stock decline and operational uncertainty for those programs. FDA Clinical Hold / Form 8‑K
• Negative Sentiment: Multiple law firms (Levi & Korsinsky, Pomerantz) have launched investigations alleging potential disclosure gaps or securities claims tied to the FDA action, increasing legal and reputational risk. Levi & Korsinsky Investigation Pomerantz Investigation
• Negative Sentiment: Media coverage (Investing.com, AAII, MSN) documents a steep market reaction and broad selloff following the FDA notice; near‑term stock performance will hinge on company updates, the FDA’s path to lifting holds, and any further safety disclosures. Investing.com Coverage

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.